Blood Biomarker Partnership Aims to Detect Alzheimer's Earlier and Less Invasively
DiamiR and AlzLabs are combining protein and microRNA blood markers with AI tools to improve early Alzheimer's detection without brain scans.
Summary
DiamiR Biosciences and AlzLabs Precision Diagnostics are collaborating to analyze blood-based biomarkers for Alzheimer's disease. Using plasma samples already confirmed for amyloid status via PET imaging, they will measure key markers including p-Tau 217, amyloid 42/40, and neurofilament light chain (NfL). These will be evaluated alongside DiamiR's CogniMIR microRNA platform to see if combined panels outperform individual markers. The goal is to develop a reliable, non-invasive blood test for brain health that could replace or supplement costly PET scans. Testing will occur in a CLIA-certified, CAP-accredited lab, adding credibility. This work is backed by a pending merger between Aptorum Group and DiamiR, with the combined company to be renamed Niki BioSolutions.
Detailed Summary
Early detection of Alzheimer's disease remains one of the biggest challenges in neurology and longevity medicine. Currently, confirming amyloid buildup in the brain requires either expensive PET imaging or invasive cerebrospinal fluid analysis. A new collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics aims to change that by developing validated blood-based biomarker panels accessible in standard clinical labs.
The partnership will analyze well-characterized plasma samples whose amyloid status has already been confirmed by amyloid PET imaging — a gold standard reference. Key biomarkers under evaluation include p-Tau 217, amyloid beta 42/40 ratio, and neurofilament light chain (NfL), each of which has shown promise individually for detecting Alzheimer's pathology in blood. These protein markers will also be tested in combination with DiamiR's proprietary CogniMIR platform, which measures brain-derived microRNAs from blood samples.
The central hypothesis is that combining protein biomarkers with microRNA signatures could yield greater diagnostic accuracy than either approach alone. If successful, such a multi-analyte panel could help clinicians identify Alzheimer's risk earlier and more affordably, without relying on neuroimaging infrastructure.
Testing will be conducted in DiamiR's CLIA-certified, CAP-accredited laboratory, which means results will meet regulated clinical standards — a meaningful step toward real-world deployment. The broader corporate context includes a pending merger between Aptorum Group and DiamiR, approved by shareholders in June 2026, that would create a new entity called Niki BioSolutions.
For health-conscious adults and clinicians, this collaboration represents a meaningful step toward routine, accessible Alzheimer's screening via a simple blood draw. However, this is still a data-generation and validation phase — no clinical test is yet commercially available from this collaboration, and results have not been published in peer-reviewed literature.
Key Findings
- Blood markers p-Tau 217, amyloid 42/40, and NfL will be evaluated alone and in combination for Alzheimer's detection.
- DiamiR's CogniMIR microRNA platform will be combined with protein biomarkers to potentially boost diagnostic accuracy.
- Plasma samples are validated against amyloid PET imaging, providing a rigorous gold-standard reference for the study.
- Testing occurs in a CLIA-certified, CAP-accredited lab, supporting potential future clinical deployment.
- A corporate merger will combine DiamiR and Aptorum into Niki BioSolutions, consolidating resources for brain health diagnostics.
Methodology
This is a corporate news report summarizing a business collaboration and research initiative announcement. It is not a peer-reviewed study. Evidence basis is a press release from Aptorum Group; no experimental results have yet been published.
Study Limitations
No study results have been published yet; this is an announcement of intent to generate data, not a research finding. Claims about diagnostic accuracy of the combined panel remain unproven. Corporate merger context may introduce promotional bias in the announcement.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: